The effects of apixaban on clot characteristics in atrial fibrillation: A novel pharmacodynamic biomarker

The effects of apixaban on clot characteristics in atrial fibrillation: A novel pharmacodynamic biomarker

Abstract Atrial fibrillation (AF) is a major risk factor for stroke. We aim to characterize AF patients and the effects of apixaban therapy in terms of clot microstructure using gel point analysis, a novel biomarker. Seventy‐eight patients were included in the study, 50 Stroke with AF (AF‐S), and 28...

Full description

Bibliographic Details
Main Authors:	Matthew J. Lawrence, Vanessa Evans, Janet Whitley, Suresh Pillai, Phylip R. Williams, James Coulson, Manju Krishnan, Peter Slade, Kieron Power, Roger H.K. Morris, Phillip A. Evans
Format:	Article
Language:	English
Published:	Wiley 2022-04-01
Series:	Pharmacology Research & Perspectives
Subjects:	anticoagulation apixaban cerebrovascular disease clot microstructure gel point and fractal analysis
Online Access:	https://doi.org/10.1002/prp2.937

Similar Items

Apixaban
by: Gianluca Airoldi, et al.
Published: (2013-03-01)

Effect of Apixaban Pretreatment on Alteplase-Induced Thrombolysis: An In Vitro Study
by: Sandra Thalerová, et al.
Published: (2021-09-01)

Rectus sheath hematoma associated with apixaban
by: Kulothungan Gunasekaran, et al.
Published: (2017-08-01)

Thrombocytopenia: A possible side effect of apixaban
by: Farid Sadaka
Published: (2019-12-01)

Preparation of Apixaban Solid Dispersion for the Enhancement of Apixaban Solubility and Permeability
by: Juseung Lee, et al.
Published: (2023-03-01)

Unexpected excessive apixaban exposure: case report of a patient with polymorphisms of multiple apixaban elimination pathways
by: Andrea Huppertz, et al.
Published: (2019-08-01)

Intracranial Hemorrhage following Lumbar Puncture in a Patient on Apixaban
by: Priyanka Vijapura, et al.
Published: (2019-09-01)

APIXABAN – FROM RECOMMENDATIONS TO EVERYDAY PRACTICE
by: L. N. ELISEEVA, et al.
Published: (2016-12-01)

Clinical Outcomes of Very Elderly Patients With Atrial Fibrillation Receiving On‐label Doses of Apixaban: J‐ELD AF Registry Subanalysis
by: Masato Okada, et al.
Published: (2021-08-01)

Apixaban: An oral anticoagulant having unique mechanism of action with better safety and efficacy profile
by: Z A Fazeel
Published: (2016-01-01)

Anticoagulant activity of apixaban can be estimated by multiple regression analysis
by: Naoko Unami, et al.
Published: (2020-12-01)

Single low-dose of apixaban in patients with atrial fibrillation after transcatheter aortic valve implantation
by: Gabriela Veiga-Fernández, et al.
Published: (2020-08-01)

Clinical and economic analysis of the use of apixaban for the treatment of venous thromboembolic events
by: O. V. Shatalova
Published: (2015-12-01)

Therapeutic potential of apixaban at different stages of management of patients with pulmonary thromboembolism
by: O. V. Averkov, et al.
Published: (2019-01-01)

Comparing the Effects of Three Heparinization Methods of Hemodialysis Set on the Amount of Clot Formation during Hemodialysis
by: M Kazemi, et al.
Published: (2005-07-01)

Traumatic Pseudoaneursym of Superficial Temporal Artery in an Octogenarian Patient Under Apixaban Therapy
by: Sertan Özyalçın, et al.
Published: (2020-02-01)

Impact of anemia on the clinical outcomes in elderly patients with atrial fibrillation receiving apixaban: J-ELD AF registry subanalysis
by: Nobuaki Tanaka, et al.
Published: (2022-06-01)

Effectiveness and Safety of Apixaban for Treatment of Venous Thromboembolism in Daily Practice
by: Stephan V. Hendriks, et al.
Published: (2020-04-01)

Venous thrombo-embolism (VTE) prevention of patients undergoing total hip and knee replacement: budget impact analysis of apixaban in Italy
by: Lorenzo Giovanni Mantovani, et al.
Published: (2013-09-01)

Evaluation of the effect of apixaban using a viscoelastic coagulation assay with Russell’s viper venom reagent
by: Kaoru Suzuki, et al.
Published: (2021-05-01)

Sustained resolution of anticoagulation related iron deficiency anemia with the use of apixaban
by: Alex Choo, et al.
Published: (2020-01-01)

Comparative pharmacoeconomic assessment of apixaban vs. standard of care for the prevention of stroke in Italian atrial fibrillation patients
by: Lorenzo Pradelli, et al.
Published: (2014-12-01)

Budget impact analysis of apixaban versus other NOACs for the prevention of stroke in Italian atrial fibrillation patients
by: Lorenzo Pradelli, et al.
Published: (2014-12-01)

Cost‑effectiveness analysis of apixaban versus other NOACs for the prevention of stroke in Italian atrial fibrillation patients
by: Lorenzo Pradelli, et al.
Published: (2014-12-01)

THE PHARMACOKINETICS OF APIXABAN IN PATIENTS WITH CARDIOEMBOLIC STROKE IN ACUTE PHASE
by: A. V. Kryukov, et al.
Published: (2016-06-01)

The economic impact associated with cerebrovascular events related to non-valvular atrial fibrillation (NVAF) in Italy: the role of apixaban
by: Lorenzo Pradelli, et al.
Published: (2014-12-01)

Apixaban, a Novel Oral Anticoagulant, Use to Resolute Arterial Patency in Radial Artery Occlusion Due to Cardiac Catheterization; A Pilot Randomized Clinical Trial
by: Afshin Amirpour, et al.
Published: (2023-11-01)

The influence of residual apixaban on bleeding complications during and after catheter ablation of atrial fibrillation
by: Yutaro Mukai, et al.
Published: (2017-10-01)

Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy
by: Robert Frank Cornell, et al.
Published: (2019-02-01)

Warfarin vs. apixaban in nonvalvular atrial fibrillation, and analysis by concomitant antiarrhythmic medication use: A national retrospective study
by: Matthew A. Wanat, et al.
Published: (2019-10-01)

Pharmacokinetics of Apixaban Among Peritoneal Dialysis PatientsPlain Language Summary
by: Winston Wing-Shing Fung, et al.
Published: (2023-08-01)

Efficacy and safety of Apixaban for the prevention of thrombosis in arteriovenous grafts
by: Arash Hedayat, et al.
Published: (2024-01-01)

Rationale and design of a study on D-dimer use to stratify patients after a first unprovoked venous thromboembolism for their risk of recurrence: extended low-dose Apixaban given only to patients with positive D-dimer results
by: Gualtiero Palareti, et al.
Published: (2022-03-01)

Comparative Effectiveness of Apixaban and Rivaroxaban Lead-in Dosing in VTE Treatment: Observational Multicenter Real-World Study
by: Omar A. Alshaya, et al.
Published: (2022-12-01)

Apixaban linearity profile for hydrotropic solubilization
by: Santosh Karajgi, et al.
Published: (2020-01-01)

Cutaneous Ulcer Caused by Apixaban Treatment Is Resolved after Replacement with Dabigatran
by: Alessandro Medoro, et al.
Published: (2022-05-01)

ORAL ANTICOAGULANTS IN THE TREATMENT OF VENOUS THROMBOEMBOLIC COMPLICATIONS: FOCUS ON APIXABAN
by: M. Yu. Gilyarov, et al.
Published: (2017-12-01)

Apixaban in low‐weight patients with cancer‐associated thrombosis: A cross sectional study of drug levels
by: Verónica Bravo Villa, et al.
Published: (2021-03-01)

Effectiveness and Safety of Apixaban in over 3.9 Million People with Atrial Fibrillation: A Systematic Review and Meta-Analysis
by: Benjamin J. R. Buckley, et al.
Published: (2022-06-01)

Safety and pharmacokinetic profile of apixaban in end‐stage renal disease: A real‐world analysis
by: Chen I. Tseng, et al.
Published: (2023-02-01)